Ito Tetsuhide, Nishimori Isao, Inoue Naoko, Kawabe Ken, Gibo Junya, Arita Yoshiyuki, Okazaki Kazuichi, Takayanagi Ryoichi, Otsuki Makoto
Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
J Gastroenterol. 2007 May;42 Suppl 18:50-8. doi: 10.1007/s00535-007-2051-y.
Autoimmune pancreatitis (AIP) has been characterized by unique clinical imaging, immunological findings, and the effectiveness of steroid therapy. A set of clinicopathological criteria for AIP was proposed by the Japan Pancreatic Society in 2002, and AIP has come to be widely recognized among general digestive clinicians. However, the indication of steroid therapy for AIP is still not well established, and furthermore the therapeutic doses and method of administration of steroid therapy is also unclear. Recently, an epidemiological survey of all the treatments used for AIP in Japan was conducted by the Research Committee of Intractable Pancreatic Diseases, and their report "Consensus for a Treatment of Autoimmune Pancreatitis" was produced. In a comparison of the results of steroid therapy and nonsteroid therapy for AIP in relation to the rate of complete remission, the recurrence rate, and the period needed to guarantee complete remission, it was thought that the administration of a steroid should be a standard therapy for AIP. However, if the diagnosis of AIP is still uncertain, steroid therapy should be given with caution. In addition, even when AIP still appears to be possible after a course of steroid therapy, a re-evaluation should be carried out taking pancreatic carcinoma into consideration. An initial steroid dose of 30-40 mg per day is recommended. With continuous and careful observations of the clinical manifestations, laboratory data, and imaging findings after administration of the initial dose of steroid for 2-4 weeks, the quantity of steroid can be reduced gradually to a maintenance dose in 2-3 months, and then reduced to 2.5-5 mg per day after remission. The recommended period of maintenance treatment is still unclear, but the administration of the steroid could be stopped after a period of about 6-12 months of treatment, although the patient should be monitored for clinical manifestations of improvement. In addition, the patient's progress should be followed taking recurrence into consideration. In order to evaluate the effectiveness of steroid therapy, follow-up observations should include biochemical examinations of blood findings such as serum gamma-globulin, IgG, and IgG 4, imaging findings, and clinical manifestations such as jaundice and abdominal discomfort.
自身免疫性胰腺炎(AIP)具有独特的临床影像学、免疫学表现以及类固醇治疗的有效性。2002年日本胰腺学会提出了一套AIP的临床病理诊断标准,自此AIP在普通消化科临床医生中得到了广泛认可。然而,AIP的类固醇治疗指征仍未明确确立,而且类固醇治疗的剂量和给药方法也不清楚。最近,难治性胰腺疾病研究委员会对日本所有用于AIP的治疗方法进行了一项流行病学调查,并发布了他们的报告《自身免疫性胰腺炎治疗共识》。在比较类固醇治疗和非类固醇治疗AIP的完全缓解率、复发率以及保证完全缓解所需时间的结果时,认为类固醇给药应作为AIP的标准治疗方法。然而,如果AIP的诊断仍不确定,则应谨慎给予类固醇治疗。此外,即使在经过一个疗程的类固醇治疗后AIP仍有可能存在,也应考虑胰腺癌进行重新评估。建议初始类固醇剂量为每天30 - 40毫克。在给予初始剂量的类固醇2 - 4周后,持续并仔细观察临床表现、实验室数据和影像学表现,类固醇剂量可在2 - 3个月内逐渐减至维持剂量,缓解后再减至每天2.5 - 5毫克。推荐的维持治疗时间仍不明确,但在治疗约6 - 12个月后可停用类固醇,不过仍应对患者进行改善的临床表现监测。此外,应考虑复发情况跟踪患者的病情进展。为了评估类固醇治疗的效果,随访观察应包括血液检查结果的生化指标,如血清γ-球蛋白、IgG和IgG4、影像学表现以及黄疸和腹部不适等临床表现。